Edition:
United States

Accelerate Diagnostics Inc (AXDX.OQ)

AXDX.OQ on NASDAQ Stock Exchange Capital Market

22.45USD
17 Nov 2017
Change (% chg)

$1.30 (+6.15%)
Prev Close
$21.15
Open
$21.35
Day's High
$22.45
Day's Low
$21.20
Volume
126,022
Avg. Vol
100,092
52-wk High
$30.45
52-wk Low
$16.85

Latest Key Developments (Source: Significant Developments)

Accelerate Diagnostics reports Q3 loss per share $0.31
Thursday, 2 Nov 2017 04:01pm EDT 

Nov 2 (Reuters) - Accelerate Diagnostics Inc :Accelerate Diagnostics Inc reports q3 2017 financial results.Q3 loss per share $0.31.Q3 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S.  Full Article

Plaintiffs dismiss class action appeal against Accelerate Diagnostics
Wednesday, 13 Sep 2017 01:05pm EDT 

Sept 13 (Reuters) - Accelerate Diagnostics Inc :Plaintiffs dismiss class action appeal against Accelerate Diagnostics.Says ‍court signed order dismissing plaintiffs' appeal of class action lawsuit filed against accelerate,certain of co's executives​.Says ‍shortly before appeal was scheduled to be argued, plaintiffs/appellants voluntarily requested that case be dismissed​.  Full Article

Accelerate Diagnostics reports Q2 loss per share $0.31
Thursday, 3 Aug 2017 04:00pm EDT 

Aug 3 (Reuters) - Accelerate Diagnostics Inc :Accelerate Diagnostics reports Q2 2017 financial results, doubles revenue generating placements.Q2 loss per share $0.31.Q2 earnings per share view $-0.30 -- Thomson Reuters I/B/E/S.  Full Article

Accelerate Diagnostics prices upsized offering of 2.75 mln shares at $28.85 per share
Tuesday, 9 May 2017 10:00pm EDT 

May 9 (Reuters) - Accelerate Diagnostics Inc :Accelerate diagnostics announces pricing of upsized public offering of common stock.Public offering of 2.75 million shares of its common stock upsized from original share offering of 2.5 million shares.Accelerate diagnostics -offering upsized from original share offering of 2.5 million shares of common stock, at price to public of $28.85 per share.  Full Article

Accelerate Diagnostics announces proposed public offering of common stock
Monday, 8 May 2017 04:15pm EDT 

May 8 (Reuters) - Accelerate Diagnostics Inc :Accelerate Diagnostics announces proposed public offering of common stock.Accelerate Diagnostics Inc says has commenced an underwritten public offering of 2.5 million shares of its common stock.  Full Article

Accelerate Diagnostics reports Q1 sales $530,000
Wednesday, 3 May 2017 04:05pm EDT 

May 3 (Reuters) - Accelerate Diagnostics Inc :Accelerate Diagnostics reports 191 instruments under contract and 3x revenue growth for first quarter 2017.Q1 sales $530,000 versus $163,000.Q1 revenue view $1.2 million -- Thomson Reuters I/B/E/S.Q1 loss per share $0.27.Q1 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S.  Full Article

Accelerate Diagnostics reports Q1 sales $530,000
Wednesday, 3 May 2017 04:05pm EDT 

May 3 (Reuters) - Accelerate Diagnostics Inc :Accelerate Diagnostics reports 191 instruments under contract and 3X revenue growth for first quarter 2017.Q1 sales $530,000 versus $163,000.Q1 loss per share $0.27.Q1 revenue view $1.2 million -- Thomson Reuters I/B/E/S.Q1 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S.  Full Article

Accelerate diagnostics submits De Novo request to FDA for phenosystem and phenotest BC kit
Monday, 11 Jul 2016 05:00am EDT 

Accelerate Diagnostics : Accelerate diagnostics submits de novo request to fda for accelerate pheno(tm) system and accelerate phenotest(tm) bc kit .Submitted de novo request for evaluation of automatic class iii designation to u.s. Fda for pheno system and phenotest bc kit.  Full Article

Accelerate Diagnostics Inc announces proposed public offering of common stock
Tuesday, 8 Dec 2015 04:01pm EST 

Accelerate Diagnostics Inc:Has commenced an underwritten public offering of $80 million of shares of its common stock.  Full Article

BRIEF-Accelerate Diagnostics says ‍on Nov 14, board increased its size to 8 members​

* Accelerate Diagnostics says ‍on Nov 14, board increased size of board to 8 members​ - SEC Filing Source text: [http://bit.ly/2iocMIO] Further company coverage: